Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
vanflyta
daiichi sankyo europe gmbh - quizartinib dihidrochloridas - leukemija, mieloidas, ūmus - antinavikiniai vaistai - gydyti ūminės mieloidinės leukemijos.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemija, mieloidas - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
